A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

Clinical trial NCT06983158 · TERMINATED

Trial details

NCT number: NCT06983158
Sponsor: Capsida Biotherapeutics, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Developmental and Epileptic Encephalopathy

Start date: 2025-07-03
Primary completion: 2026-03-25
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.